Recent developments highlight Iovance's record third quarter 2026 revenue driven by Amtagvi sales, ongoing pipeline progress, and financial results including a net loss for the quarter.

• Iovance reported record third quarter 2026 revenue of approximately $122 million, driven by Amtagvi sales and lower R&D costs [N1].
• The Q3 2026 earnings call emphasized growth in Amtagvi sales and progress in the clinical pipeline [N2].
• The company reported a net loss for Q3 2026 but revenue exceeded prior periods [N6].
• Iovance continues to expand clinical trial activities and manufacturing capabilities to support product commercialization [N4].
• The company recognizes revenue from Proleukin and Amtagvi, with payment terms ranging from 45 to 105 days [N5].

Iovance has achieved commercialization of its first internally developed product, Amtagvi, with record quarterly revenues reported. The company is advancing its pipeline through ongoing clinical trials and expanding manufacturing capabilities. Regulatory approvals and market acceptance of its TIL therapies could enhance its commercial footprint. Strategic collaborations and orphan drug designations may provide competitive advantages and potential exclusivity periods. Strong liquidity ratios support operational flexibility in the near term.

Iovance has a history of operating losses and an accumulated deficit nearing $3 billion, reflecting substantial ongoing investment without profitability. The company faces risks related to manufacturing complexities, reliance on limited suppliers, and regulatory uncertainties that could delay product availability or increase costs. Additional financing needs may lead to dilution or operational restrictions. Market acceptance of novel therapies is uncertain, and competitive pressures from other biotech and pharmaceutical companies are significant. Economic and geopolitical uncertainties may further impact financial and operational performance.

Iovance's moat is based on its pioneering approach to individualized TIL therapies for cancer treatment, including proprietary manufacturing processes and orphan drug designations. The company benefits from its early commercial-stage status with approved products like Amtagvi and Proleukin, and collaborations with governmental and academic partners. However, the complexity of manufacturing, reliance on limited suppliers, and regulatory hurdles present ongoing challenges. The company's ability to scale manufacturing efficiently and maintain regulatory compliance will be critical to sustaining competitive advantage.

• Operating Losses and Profitability: Iovance has a history of operating losses and may continue to incur losses without achieving profitability, which could impact its financial stability.
• Need for Additional Financing: The company may require additional capital to fund operations, clinical development, and commercialization. Failure to secure financing could restrict operations or require relinquishing rights to technologies.
• Manufacturing Complexities: Manufacturing of cell-based therapies is complex, with risks related to process development, quality control, and scaling. Difficulties could delay supply or increase costs.
• Supply Chain Dependencies: Reliance on limited suppliers and sole source vendors for biological raw materials and specialized equipment could impair manufacturing and supply capabilities.
• Regulatory Risks: Extensive FDA and foreign regulatory requirements may cause delays or additional costs. Post-marketing requirements could limit commercial prospects.
• Market Acceptance and Competition: Novel therapies face uncertainties in market acceptance, reimbursement coverage, and competition from other biotech and pharmaceutical companies.
• Operational and Organizational Growth: Expanding manufacturing capacity and commercial operations may present management challenges and increase fixed expenses.
• Economic and Geopolitical Uncertainties: Global economic instability, inflation, and geopolitical conflicts could materially adversely affect business and financial results.

• Iovance Biotherapeutics, Inc. is a commercial-stage biopharmaceutical company focused on individualized cancer therapies using tumor-infiltrating lymphocytes (TIL).
• The company began generating revenue from the sale of Proleukin® after acquiring it in May 2023 and from Amtagvi® starting in Q2 2024.
• Revenue recognition follows ASC 606, with Amtagvi revenue recognized upon infusion and Proleukin revenue recognized upon shipment or receipt.
• As of September 30, 2026, Iovance had cash and cash equivalents of $57.9 million and short-term investments of $318.4 million, totaling approximately $376.3 million in liquid assets.
• Current assets as of September 30, 2026 were $549.6 million, with current liabilities of $105.8 million, resulting in a current ratio of 5.2 and a cash ratio of 2.37.
• The company reported a net loss of $22.3 million for Q3 2026 and an accumulated deficit of $2.9 billion as of September 30, 2026.
• Iovance reported record third quarter 2026 revenue of approximately $122 million, driven by Amtagvi sales.
• The company is executing the U.S. launch of Amtagvi and expanding clinical trial activities to demonstrate effectiveness of product candidates.
• Iovance faces risks including a history of operating losses, need for additional financing, manufacturing complexities, reliance on limited suppliers, regulatory uncertainties, and competition.
• The company relies on third parties for manufacturing and commercialization services and may face challenges scaling manufacturing capacity.
• Regulatory approvals and market acceptance of products are uncertain and may impact commercial success.
• Iovance has orphan drug designation for lifileucel in certain indications but maintaining such designations is not guaranteed.
• The company is subject to extensive FDA and foreign regulatory requirements, which may cause delays or additional costs.
• Iovance's financial condition and operations could be materially affected by geopolitical instability, inflation, and capital market disruptions.
• The company has substantial fixed expenses and contractual commitments expected to increase as it expands operations.
• Iovance's future funding needs depend on clinical trial progress, regulatory approvals, commercialization success, manufacturing scale-up, and potential acquisitions or collaborations.